| Literature DB >> 34447257 |
Huan Zhang1,2, Jin Wang1, Weiying Zhou2, Ming Yang3, Rui Wang1, Xin Yan4, Yun Cai1.
Abstract
PURPOSE: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections have become a serious threat with high morbidity and mortality. Early identification of risk factors for CRKP infections is important, but these factors are still controversial. Therefore, we aimed to identify the risk factors and clinical outcomes of CRKP infections. PATIENTS AND METHODS: The retrospective, single-center study was carried out in the respiratory intensive care unit of the Chinese People's Liberation Army General Hospital from 2017 to 2020. Patients infected with K. pneumoniae were included and categorized into the CRKP group and carbapenem-sensitive K. pneumoniae (CSKP) group based on the susceptibility to carbapenems. The independent risk factors were investigated by univariate analysis and multivariate logistic regression analysis. The clinical outcomes were also evaluated between the two groups.Entities:
Keywords: Klebsiella pneumoniae; carbapenems; prognosis; resistance; risk factors
Year: 2021 PMID: 34447257 PMCID: PMC8382964 DOI: 10.2147/IDR.S317233
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Characteristics of Patients in the CRKP and CSKP Groups
| Variable | Total (n=138) | CRKP (n=97) | CSKP (n=41) |
|---|---|---|---|
| Age (year) | 80.5 (62.0–86.3) | 84.0 (74.0–88.0) | 77.5 (55.8–87.0) |
| Male (n, %) | 108 (78.3) | 75 (77.3) | 33 (80.5) |
| Height (cm) | 170.0 (165.0–173.0) | 170.0 (162.0–173.5) | 170.0 (167.5–173.3) |
| Weight (kg) | 64.6±12.0 | 65.3±12.3 | 63.3±11.7 |
| BMI (kg/m2) | 22.8±4.0 | 23.2±4.0 | 22.1±4.1 |
| Sputum | 73 (52.9) | 49 (50.5) | 24 (58.5) |
| Tracheal aspirates | 37 (26.8) | 26 (26.8) | 11 (26.8) |
| Urine | 8 (5.8) | 7 (7.2) | 1 (2.4) |
| Catheterb | 6 (4.3) | 6 (6.2) | 0 (0.0) |
| Blood | 6 (4.3) | 5 (5.2) | 1 (2.4) |
| Bronchoalveolar lavage fluid | 6 (4.3) | 2 (2.1) | 4 (9.8) |
| Othersc | 2 (1.4) | 2 (2.1) | 0 (0.0) |
| Pneumonia | 130 (94.2) | 94 (96.9) | 36 (87.8) |
| Bloodstream infections | 31 (22.5) | 24 (24.7) | 7 (17.1) |
| Urinary tract infections | 24 (17.4) | 22 (22.7) | 2 (4.9) |
| Catheter-related infections | 9 (6.5) | 8 (8.2) | 1 (2.4) |
| Othersd | 2 (1.4) | 2 (2.1) | 0 (0.0) |
Notes: aThe normal distribution of quantitative data was judged by Kolmogorov–Smirnov test. For normally distributed quantitative data (weight and BMI in this study), they were described as mean ±S.D., while the non-normally distributed ones (age and height) were expressed as median (IQR). bThe specimen of the catheter was referred as endotracheal, venous, drainage, or urinary catheter. cOther specimens were referred to one wound secretion and one pleural fluid. dOther infections were referred to one skin and soft tissue infection and empyema.
Abbreviations: n, sample size; %, the percentage; CRKP, carbapenem-resistant Klebsiella pneumoniae; CSKP, carbapenem-sensitive Klebsiella pneumoniae.
Univariate Analysis of Risk Factors for Infections Caused by CRKP
| Variable | CRKP (n=97) | CSKP (n=41) | ||
|---|---|---|---|---|
| Age (year) | 84.0 (74.0–88.0) | 77.5 (55.8–87.0) | −2.287 | |
| Male (n, %) | 75 (77.3) | 33 (80.5) | 0.170 | 0.680 |
| Height (cm) | 170.0 (162.0–173.5) | 170.0 (167.5–173.3) | −0.376 | 0.707 |
| Weight (kg) | 65.3±12.3 | 63.3±11.7 | −0.668 | 0.506 |
| BMI (kg/m2) | 23.2±4.0 | 22.1±4.1 | −1.136 | 0.259 |
| Hb (g/L) | 90.5±21.4 | 104.2±22.1 | 3.395 | |
| WBC (109/L) | 10.0 (7.5–13.3) | 8.3 (6.3–11.5) | −0.261 | 0.794 |
| ANC (%) | 85.1 (76.5–90.8) | 80.8 (76.3–91.0) | −0.042 | 0.966 |
| PLT (109/L) | 134.0 (81.0–182.5) | 187.5 (83.0–262.8) | −1.542 | 0.123 |
| ALB (g/L) | 34.6±5.1 | 34.4±5.9 | −0.160 | 0.873 |
| ALT (U/L) | 13.6 (8.2–28.1) | 16.2 (12.3–22.3) | −1.154 | 0.249 |
| AST (U/L) | 26.5 (16.6–57.3) | 20.4 (15.3–33.1) | −2.301 | |
| Scr (μmol/L) | 84.6 (58.5–162.5) | 81.7 (50.6–114.3) | −1.499 | 0.134 |
| Hypertension | 42 (43.3) | 11 (26.8) | 3.305 | 0.069 |
| Diabetes | 29 (29.9) | 6 (14.6) | 3.546 | 0.060 |
| Cardiovascular diseases | 58 (59.8) | 16 (39.0) | 4.999 | |
| Hepatic dysfunction | 44 (45.4) | 18 (43.9) | 0.025 | 0.875 |
| Renal dysfunction | 40 (41.2) | 9 (22.0) | 4.681 | |
| Lung diseases | 35 (36.1) | 13 (31.7) | 0.243 | 0.622 |
| Digestive diseases | 26 (26.8) | 7 (17.1) | 1.500 | 0.221 |
| Nervous diseases | 48 (49.5) | 17 (41.5) | 0.744 | 0.388 |
| Malignancy | 15 (15.5) | 3 (7.3) | 1.686 | 0.194 |
| Fracture | 8 (8.2) | 7 (17.1) | 1.496 | 0.221 |
| Hypoalbuminemia | 54 (55.7) | 19 (46.3) | 1.007 | 0.316 |
| Anemia | 44 (45.3) | 11 (26.8) | 4.129 | |
| ≥three types of comorbidities | 87 (89.7) | 27 (65.9) | 11.398 | |
| Hospitalization | 38 (39.2) | 7 (17.1) | 6.406 | |
| Hospitalization ≥30 days | 18 (18.6) | 2 (4.9) | 4.351 | |
| Glucocorticoids | 17 (17.5) | 4 (9.8) | 1.348 | 0.246 |
| β-lactam/β-lactamase inhibitors | 28 (28.9) | 10 (24.4) | 0.289 | 0.591 |
| Carbapenems | 38 (39.2) | 6 (14.6) | 7.992 | |
| Aminoglycosides | 5 (5.2) | 2 (4.9) | 0.000 | 1.000 |
| Macrolides | 16 (16.5) | 4 (9.8) | 1.056 | 0.304 |
| Tetracyclines | 5 (5.2) | 4 (9.8) | 0.388 | 0.533 |
| Glycopeptides | 20 (20.6) | 7 (17.1) | 0.230 | 0.631 |
| Quinolones | 25 (25.8) | 3 (7.3) | 6.070 | |
| Sulfonamides | 7 (7.2) | 0 (0.0) | 1.798 | 0.180 |
| Linezolid | 16 (16.5) | 5 (12.2) | 0.413 | 0.520 |
| Antifungal agents | 30 (30.9) | 7 (17.1) | 2.819 | 0.093 |
| Mechanical ventilation | 68 (70.1) | 16 (39.0) | 11.687 | |
| Peripheral venous catheterization | 33 (34.0) | 7 (17.1) | 4.021 | |
| Central venous catheterization | 49 (50.5) | 9 (22.0) | 9.651 | |
| Indwelling drainage catheter | 4 (4.1) | 1 (2.4) | 0.000 | 1.000 |
| Indwelling gastric catheter | 53 (54.6) | 13 (31.7) | 6.073 | |
| Indwelling urinary catheter | 72 (74.2) | 17 (41.5) | 13.509 | |
Notes: Bold P<0.05 indicates statistical significance. aKolmogorov–Smirnov test was used to judge the normal distribution of quantitative data. For normally distributed quantitative data (weight, BMI, Hb, and ALB in this study), they were described as mean ±S.D., while the non-normally distributed ones were expressed as median (IQR); bQualitative data were expressed as number and percentage (n (%)). cTo compare the difference of variables between the two groups, the qualitative data were analyzed by Pearson Chi-square test (χ2) or Fisher’s exact test with theoretical total numbers less than 5. Similarly, the Student’s t-test (t) was used for quantitative data with normal distribution. Otherwise, the Wilcoxon Rank Sum Test (z) was used.
Abbreviations: CRKP, carbapenem-resistant Klebsiella pneumoniae; CSKP, carbapenem-sensitive Klebsiella pneumoniae; n, sample size; BMI, Body Mass Index; Hb, hemoglobin; WBC, white blood cell count; ANC, neutrophil ratio; PLT, platelet; ALB, serum albumin; ALT, glutamic pyruvic transaminase; AST, glutamic oxaloacetic transaminase; Scr, serum creatinine.
Multivariate Logistic Regression Analysis of Risk Factors for Infections Caused by CRKP
| Variable | OR | 95% CI | |
|---|---|---|---|
| Age (year) | – | – | 0.295 |
| Hb | – | – | 0.178 |
| AST | – | – | 0.465 |
| Hypertension | – | – | 0.559 |
| Diabetes | – | – | 0.196 |
| Cardiovascular diseases | – | – | 0.449 |
| Renal dysfunction | – | – | 0.130 |
| Anemia | – | – | 0.336 |
| ≥three types of comorbidities | 5.465 | 1.773–16.848 | |
| Hospitalization | 4.279 | 1.517–12.072 | |
| Hospitalization ≥30 days | – | – | 0.198 |
| Carbapenems | – | – | 0.090 |
| Quinolones | 5.872 | 1.466–23.516 | |
| Antifungal agents | – | – | 0.545 |
| Mechanical ventilation | – | – | 0.816 |
| Peripheral venous catheterization | – | – | 0.558 |
| Central venous catheterization | – | – | 0.260 |
| Indwelling gastric catheter | – | – | 0.671 |
| Indwelling urinary catheter | 5.035 | 2.067–12.264 |
Note: Bold P<0.05 indicates statistical significance.
Abbreviations: CRKP, carbapenem-resistant Klebsiella pneumoniae; OR, odds ratio; CI, confidence interval; Hb, hemoglobin; AST, glutamic oxaloacetic transaminase.
Analysis of Clinical Outcomes for CRKP and CSKP Patients
| Clinical Outcomes (n, %) | CRKP (n=95) | CSKP (n=40) | ||
|---|---|---|---|---|
| Improved | 55 (57.9) | 33 (82.5) | 7.509 | 0.006 |
| Worsened and death | 40 (42.1) | 7 (17.5) |
Notes: The difference in clinical outcomes between the CRKP and CSKP groups was analyzed by the Pearson Chi-square test (χ2), with P<0.05 indicating statistical significance. Improved was defined as resolution or partial resolution of clinical symptoms and signs of infections, as well as gradual normalization of laboratory findings. Worsened was defined as worsening of presenting symptoms or signs of infections and persistently abnormal laboratory findings without any tendency of improvement. Death was defined as all-cause in-hospital mortality during the whole hospitalization.
Abbreviations: CRKP, carbapenem-resistant Klebsiella pneumoniae; CSKP, carbapenem-sensitive Klebsiella pneumoniae; n, sample size; %, the percentage of specific clinical outcome in the CRKP or CSKP group.
Figure 1Kaplan-Meier survival curves for CRKP and CSKP patients (Log rank test, P=0.029).